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Weakening HIV
One person’s fight against an HIV infection can decrease the virus’s 
ability to threaten its next victim, say Goepfert et al. (page 1009). 
Mutations that help the virus survive in one host decrease its ability 
to replicate in the next.
HIV mutations that help the virus bypass the host’s immune system 
often fall within gag. This gene is a favorite target for mutations because, 
for some reason, Gag epitopes that are presented by HLA B alleles create 
the most productive immune response. But Gag is also critical for viral 
replication. The infected individual doesn’t benefit from replication-
dampening gag mutations, as the virus still escapes from cytotoxic T cells.
Goepfert and colleagues now find, however, that the resulting 
decreased replication may benefit the patient’s sexual partner. Their 
study of 114 couples found that individuals who were infected by 
partners with certain HLA B alleles had much lower viral levels when 
more than five gag mutations were present. Viral levels were lowest in 
newly infected individuals who did not have the same type of HLA B 
alleles as their partners, perhaps 
because the recipients’ T cells 
efficiently targeted non-Gag 
epitopes of the mutated virus.
At least five gag mutations 
were needed to reduce viral 
load significantly. This 
threshold might explain why 
a T cell vaccine that induces 
immune responses against two 
Gag epitopes failed in a recent 
trial. Better results might be 
gained by targeting more 
epitopes. 
Refilling an empty niche with proliferating 
CD8+ T cells can cause autoimmune disease, 
say Tajima et al. (page 1019).
Infusion of naive T cells into an environ-
ment where there are few native T cells—such 
as in patients undergoing cancer therapy—spurs 
two kinds of proliferation. T cells activated by 
non-self-peptide/MHC complexes proliferate 
rapidly, whereas those activated by self-peptide/
MHC in the presence of cytokines such as IL-7 
and IL-15 proliferate slowly. CD4+ T cells that 
proliferate by these methods have previously 
been shown to drive the inflammation seen in 
several autoimmune diseases.
Tajima et al. now find a new variation in 
homeostatic proliferation of CD8+ T cells that 
also induces autoimmunity. In gut lymph nodes 
of T cell–deficient mice, injected CD8+ T cells 
proliferated rapidly in response to IL-6. This 
inflammatory cytokine was found at high levels 
in these lymph nodes, perhaps due to their 
proximity to the bacterium-laden gut.
The mice developed a thicker gut epithelium 
and lost weight—signs of an autoimmune disease 
called colitis. T cell–injected mice treated with an 
IL-6–blocking antibody or with bacterium-
depleting drugs, however, remained healthy.
The proliferating T cells secreted several 
inflammatory cytokines, including IL-17. The 
IL-17 alone seemed to be responsible for the 
colitis, as mice injected with T cells that were 
unable to produce IL-17 remained healthy. If 
these IL-17–producing CD8+ T cells are 
found in patients suffering from diseases such 
as colitis, the anti–IL-6 antibody might be a 
good therapeutic option. 
A trick presentation
On page 1201, Huang et al. find that an antigen-
presenting protein suffers from an identity crisis: 
it looks like MHC class I but behaves like MHC 
class II.
This molecule, MR1, is recognized by a subset of 
gut-roving T cells. When MR1 carries the right 
antigen, these T cells suppress gut inflammation, but 
the identity of that antigen is a mystery. Because MR1 
is structurally similar to MHC class I molecules, which 
usually pick up proteasome-processed peptides in the 
ER, MR1 was thought to do the same.
This notion is now disproved by Huang et al., 
who show that MR1-expressing cells treated with 
proteasome inhibitors or lacking ER peptide–loading 
chaperones can still activate these T cells. Instead, they 
found, MR1 picked up its antigens in endosomes, 
where MHC class II molecules get theirs.
MR1 bound to a chaperone called the invariant 
chain, which ferries MHC class II molecules from 
the ER into endosomes. There, it bound another 
chaperone, called DM, which loads them up with 
peptides. MR1-expressing cells that lacked the 
invariant chain were unable to activate gut T cells, 
whereas high levels of this protein increased their 
activation.
The immune-suppressing ability of MR1-activated 
T cells suggests that they might prevent the gut 
from attacking its helpful resident flora. The authors 
therefore speculate that the MR1 ligand might be 
derived from one or more of these residents. 
Autoimmune colitis (top) 
caused by homeostatically 
proliferating CD8+ T cells is 
resolved in mice injected with 
anti–IL-6 antibody (bottom).
HIV levels are lower in patients 
infected with viruses carrying 5 
HLA B–associated Gag mutations.
Dangers of restocking T cells